- Poster presentation
- Open Access
Clinical features of ESBL-producing E. coli responsible for bloodstream infections in French patients and molecular characterization of isolates
© Gaultier et al; licensee BioMed Central Ltd. 2015
Published: 16 June 2015
We conducted an annually bloodstream infection (BSI) survey into hospitals overlapping the Centre France region (2.6 million). Since 2005, the incidence of BSIs associated with ESBL-producing E. coli (ESBLEc) increased.
To improve the understanding of the pathway and the determination of the risk factors of ESBLEc-BSIs.
For each BSI, were reported patient age, sex, recent hospitalization, living in nursing home, recent antibiotherapy, urinary catheterization, BSI source, death within 7days of diagnosis.
BSI isolates were studied: antimicrobial susceptibility, determination of molecular mechanism associated with ESBL-production, genetic diversity of ESBLEc (MLST).
During the survey (474,953 PDs), 443 E. coli BSI were identified, including 31 ESBLEc (7.0%; 30/31 CTX-M). Incidence of community acquired(CA)- and healthcare associated(HCA)-BSI were 0.47/100,000 and 0.040/1,000 PDs, respectively.
For ESBLEc-CA-BSIs, male/female ratio was 1.4, median age 80, urinary BSI source in 50% of cases, recent antibiotherapy in 33 %. Most ESBLEc were resistant to fluoroquinolones (67%), SXT/TMP (67%). High genetic diversity (8 STs including 4 ST131).
For ESBLEc-HCA-BSI, male/female ratio was 0.9, median age 75, urinary BSI source in 63% of cases (recent catheterization in 1/2), recent antibiotherapy in 58%. Most ESBLEC were resistant to fluoroquinolones (79%), SXT/TMP (63%). Low genetic diversity (9 STs including 7 ST131).
Among BSI, ESBLEc-BSI were associated with healthcare (p=0.004), long-stay unit (p=0.018), recent antibiotherapy (p=0.002). ESBLEc were associated with resistance to fluoroquinolones, SXT/TMP and genta./tobramycine (p<0.001).
Among ESBLEc-BSI, clinical determinants and BSI characteristics similar whatever the clonal group excepted for ST131 associated with long-stay unit (p=0.042).
Among ST131-BSI, clinical determinants and BSI characteristics similar for ESBLEc and non ESBLEc excepted median age higher in ESBLEc (80/67).
Recent antibiotherapy (and easy spread into long-stay units for ST131): likely the major risk factor for ESBLEc BSI.
Disclosure of interest
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.